Vanguard Group’s Dimension Therapeutics, Inc DMTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-610,285
Closed -$3.66M 4165
2017
Q3
$3.66M Buy
610,285
+96,341
+19% +$250K ﹤0.01% 3226
2017
Q2
$745K Sell
513,944
-156,948
-23% -$213K ﹤0.01% 3644
2017
Q1
$1.17M Buy
670,892
+23,263
+4% +$61.7K ﹤0.01% 3537
2016
Q4
$2.82M Sell
647,629
-25,054
-4% -$133K ﹤0.01% 3244
2016
Q3
$5.37M Buy
672,683
+246,518
+58% +$1.78M ﹤0.01% 2964
2016
Q2
$2.56M Buy
426,165
+348,311
+447% +$2.65M ﹤0.01% 3281
2016
Q1
$610K Buy
77,854
+51,388
+194% +$405K ﹤0.01% 3739
2015
Q4
$298K Buy
+26,466
New +$335K ﹤0.01% 3943

Vanguard Group's DMTX Position: Q4 2017 in Review

Vanguard Group sold out of Dimension Therapeutics, Inc (DMTX) in Q4 2017, closing a stake of 610,285 shares — an estimated $3.66M sold.

Vanguard Group first reported a position in DMTX in Q4 2015 and held it in 8 quarters. The position peaked at $5.37M in Q3 2016. 0 funds tracked by Wall St. Rank hold DMTX as of Q4 2017.

  • Vanguard Group reported no remaining Dimension Therapeutics, Inc position as of Q4 2017 after selling out during the quarter.
  • Vanguard Group sold 610,285 Dimension Therapeutics, Inc shares in Q4 2017, an estimated $3.66M.
  • Vanguard Group first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 8 quarters.
  • Vanguard Group's Dimension Therapeutics, Inc position peaked at $5.37M in Q3 2016.
  • 0 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q4 2017.

Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.